In Giorgio 2022,[53] a robust and interpretable machine learning approach is utilized to quantify interactions between key pathological markers (β‐amyloid, medial temporal lobe atrophy, tau and APOE 4) at mildly impaired and asymptomatic stages of AD. This evidence concerns the gene MAPT and Alzheimer disease.